生物活性 | |||
---|---|---|---|
描述 | Glucagon, encoded by proglucagon gene and manufactured by the α cells in the pancreatic islets, stimulates glucose production through glycogenolysis and gluconeogenesis. Glucagon and insulin work together to maintain euglycemia and glucose transport to the tissues. The blood glucose levels determine whether glucagon or insulin is activated or inhibited. Low plasma glucose stimulates glucagon secretion which in turn promotes hepatic gluconeogenesis and glycogenolysis to normalize plasma glucose levels. Administration of glucagon increases glucose levels via gluconeogenesis and glycogenolysis in fasted or fed animals and in humans. But excessive glucagon might result from a tumor in the tail or the body of the pancreas, potentially leading to the glucagonoma syndrome, comprising weight loss, necrolytic migratory erythema (NME), diabetes, and mucosal abnormalities including stomatitis, cheilitis, and glossitis [3]. | ||
作用机制 | Glucagon binds to its membrane-bound receptor, a seven-pass transmembrane G-protein-coupled receptor [3]. |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00655603 | Type 2 Diabetes Mellitus | Not Applicable | Unknown | September 2009 | - |
NCT00515801 | Diabetes Mellitus, Type 1 | Phase 2 Phase 3 | Completed | - | Switzerland ... 展开 >> University Hospital Basel Basel, Switzerland, 4031 收起 << |
NCT03667053 | Hypoglycemia | Phase 3 | Recruiting | August 1, 2019 | United States, California ... 展开 >> AMCR Institute, Inc Recruiting Escondido, California, United States, 92025 Contact: Tim Bailey 收起 << |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
0.29mL 0.06mL 0.03mL |
1.44mL 0.29mL 0.14mL |
2.87mL 0.57mL 0.29mL |
参考文献 |
---|